TY  - JOUR
AU  - Radtke, Jan Philipp
AU  - Giganti, Francesco
AU  - Wiesenfarth, Manuel
AU  - Stabile, Armando
AU  - Marenco, Jose
AU  - Orczyk, Clement
AU  - Kasivisvanathan, Veeru
AU  - Nyarangi-Dix, Joanne Nyaboe
AU  - Schütz, Viktoria
AU  - Dieffenbacher, Svenja
AU  - Görtz, Magdalena
AU  - Stenzinger, Albrecht
AU  - Roth, Wilfried
AU  - Freeman, Alex
AU  - Punwani, Shonit
AU  - Bonekamp, David
AU  - Schlemmer, Heinz-Peter
AU  - Hohenfellner, Markus
AU  - Emberton, Mark
AU  - Moore, Caroline M
TI  - Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
JO  - PLOS ONE
VL  - 14
IS  - 8
SN  - 1932-6203
CY  - San Francisco, California, US
PB  - PLOS
M1  - DKFZ-2019-02057
SP  - e0221350 -
PY  - 2019
AB  - Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men.The original RM was based on data of 670 biopsy-naïve men from Heidelberg University Hospital who underwent mpMRI with PI-RADS scoring prior to MRI/TRUS-fusion biopsy 2012-2015. Validity was tested by a consecutive cohort of biopsy-naïve men from Heidelberg (n = 160) and externally by a cohort of 133 men from University College London Hospital (UCLH). Assessment of validity was performed at fusion-biopsy by calibration plots, receiver operating characteristics curve and decision curve analyses. The RM`s performance was compared to ERSPC-RC3, ERSPC-RC3+PI-RADSv1.0 and PI-RADSv1.0 alone.SPC was detected in 76 men (48
LB  - PUB:(DE-HGF)16
C6  - pmid:31450235
DO  - DOI:10.1371/journal.pone.0221350
UR  - https://inrepo02.dkfz.de/record/144615
ER  -